EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies

Stacie Hudgens, Srdan Verstovsek, Lysbeth Floden, Claire N Harrison, Jeanne Palmer, Vikas Gupta, Donal McLornan, Mary Frances McMullin, Jean-Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, Maria Laura Fox und 9 weitere

Value in Health · 2024

DOI: 10.1016/j.jval.2024.01.014 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Value in Health, 2024. Verfasst von Stacie Hudgens und 20 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Outcomes Solutions, Tucson, AZ, USA. Electronic address: stacie.hudgens@clinoutsolutions.com. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrimidines, Quality of Life. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Cancer Research UK, Sierra Oncology, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Patients with myelofibrosis develop symptoms due to bone marrow fibrosis, systemic inflammation, and/or organomegaly. Alleviating symptoms improves overall quality of life. Clinical trials have historically defined symptom response as a reduction of at least 50% in Total Symptom Score at week 24 compared with baseline. Whether 50% constitutes a meaningful benefit has not been established. This study determined the meaningful change threshold (MCT) for 2 momelotinib phase III trials, SIMPLIFY-1 and SIMPLIFY-2. METHODS: The absolute and percentage MCT was determined using anchor-based methods applied to the modified Myeloproliferative Neoplasm Symptom Assessment Form v2.0 and Patient Global Impression of Change. MCTs were applied retrospectively to determine responder rates. Generalized estimating equations estimated the treatment-related difference in likelihood of improvement. RESULTS: In SIMPLIFY-1, a Janus kinase inhibitor-naive population, the MCT was 8 points. In SIMPLIFY-2, a previously Janus kinase inhibitor-treated population, the MCT was 6 points. A 32% MCT was determined in both studies, showing that the historic 50% reduction threshold may be a conservative choice. In SIMPLIFY-1, a similar proportion of patients achieved responder status with 24 weeks of momelotinib or ruxolitinib therapy based on the absolute MCT (39% vs 41%, respectively). In SIMPLIFY-2, a significantly greater proportion of patients treated with momelotinib achieved responder states compared with best available therapy based on absolute and percent change MCTs. CONCLUSIONS: This study demonstrates that momelotinib provided clinically meaningful symptom benefit for patients with myelofibrosis and provides insight into the appropriateness of the symptom change threshold used in historical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPyrimidinesQuality of LifeHumansFemaleMaleMiddle AgedAgedTreatment OutcomeRetrospective StudiesPyrazolesBenzamidesNitriles

Stichwörter der Autor:innen

Janus kinase inhibitormeaningful change thresholdmomelotinibmyelofibrosis

Substanzen

PyrimidinesN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamidePyrazolesBenzamidesNitrilesruxolitinib

Autor:innen und Institutionen

  • Clinical Outcomes Solutions, Tucson, AZ, USA. Electronic address: stacie.hudgens@clinoutsolutions.com.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Clinical Outcomes Solutions, Tucson, AZ, USA.
  • Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, England, UK.
  • Department of Hematology, Mayo Clinic, Phoenix, AZ, USA.
  • Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.

Förderung

  • Cancer Research UK
  • Sierra Oncology
  • GlaxoSmithKline

Zitieren

APA

Hudgens, S., Verstovsek, S., Floden, L., Harrison, C. N., Palmer, J., Gupta, V., McLornan, D., McMullin, M. F., Kiladjian, J. J., Foltz, L., Platzbecker, U., Fox, M. L., Mead, A. J., Ross, D. M., Oh, S. T., Perkins, A. A., Leahy, M. F., Deheshi, S., Donahue, R., …, & Mesa, R. A. (2024). Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies. Value in Health. https://doi.org/10.1016/j.jval.2024.01.014

Vancouver

Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, et al. Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies. Value in Health. 2024. doi:10.1016/j.jval.2024.01.014

BibTeX
@article{Hudgens2024,
  author = {Hudgens, Stacie and Verstovsek, Srdan and Floden, Lysbeth and Harrison, Claire N and Palmer, Jeanne and Gupta, Vikas and McLornan, Donal and McMullin, Mary Frances and Kiladjian, Jean-Jacques and Foltz, Lynda and Platzbecker, Uwe and Fox, Maria Laura and Mead, Adam J and Ross, David M and Oh, Stephen T and Perkins, Andrew A and Leahy, Michael F and Deheshi, Samineh and Donahue, Rafe and Klencke, Barbara J and Mesa, Ruben A},
  title = {Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies},
  journal = {Value in Health},
  year = {2024},
  doi = {10.1016/j.jval.2024.01.014}
}
Kostenlos starten →